Steven Engle is the CEO of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Previously, Mr. Engle served as CEO of Averigon, an advisory firm to the life science industry, and as Chairman and CEO of XOMA and La Jolla Pharmaceutical Company. Mr. Engle is chairman of Prescient Therapeutics, a clinical stage oncology company, and a director on the board of AROA, a developer and marketer of regenerative products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with a focus in biomedical engineering.
What if we could halt or reverse the diseases associated with aging and extend the amount of…